Appendix 4G
April 30, 2020
Imagion Biosystems has released Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations. Read Appendix 4G
Category: Investor updates
Annual Report to Shareholders
April 30, 2020
Imagion Biosystems has released its Annual Report to Shareholders for the year ended 31 December 2019. Read the Annual Report.
Appendix 2A – Vesting of Performance Rights
April 29, 2020
Imagion Biosystems announces that Appendix 2A – Vesting of Performance Rights has been released to the market. Read Appendix 2A – Vesting of Performance Rights.
Appendix 2A — Renounceable Rights Issue and Placement
April 28, 2020
Imagion Biosystems has announced Appendix 2A — Application for quotation of +securities. Read Appendix 2A.
Imagion Biosystems Updates Capital Raise to $2.5 Million
April 28, 2020
Imagion Biosystems Limited previously advised that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million. To accommodate
Second Supplementary Prospectus
April 28, 2020
Imagion Biosystems has announced a Secondary Supplementary Prospectus. Read the Secondary Supplementary Prospectus.
Proposed Issue of Securities
April 28, 2020
Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.
Imagion Biosystems Trading Halt
April 24, 2020
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in a trading halt at the request of IBX, pending it releasing an announcement. Unless
Imagion Rights Issue Oversubscribed Raising $3 Million
April 23, 2020
Imagion Biosystems Limited is pleased to advise that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million.
Supplementary Prospectus
April 23, 2020
A supplementary prospectus has been lodged with the Australian Securities and Investments Commission. This supplementary prospectus is intended to be read with the prospectus dates